Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. - Wikidata - awgldk - TriplyDB

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

http://www.wikidata.org/entity/Q33377602

about

TPO receptor agonist for chronic idiopathic thrombocytopenic purpura Medical treatments for idiopathic thrombocytopenic purpura during pregnancy Clinical indications for thrombopoietin and thrombopoietin-receptor agonists Advances in Diagnosis and Treatments for Immune Thrombocytopenia Current Management of Primary Immune Thrombocytopenia Phenotyping bleeding Childhood immune thrombocytopenia: Clinical presentation and management The European Medicines Agency review of eltrombopag (Revolade) for the treatment of adult chronic immune (idiopathic) thrombocytopenic purpura: summary of the scientific assessment of the Committee for Medicinal Products for Human Use Eltrombopag for the treatment of aplastic anemia: current perspectives The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence Eltrombopag in aplastic anemia Eltrombopag modulates reactive oxygen species and decreases acute myeloid leukemia cell survival Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.Compromised ITAM-based platelet receptor function in a patient with immune thrombocytopenic purpura.Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.Nitric oxide in immune thrombocytopenic purpura.Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults.Treatment of immune thrombocytopenic purpura: focus on eltrombopag.Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases.Thrombopoietin and platelet production in chronic immune thrombocytopenia.New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents.Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag.Increasing platelets without transfusion: is it time to introduce novel thrombopoietic agents in neonatal care?Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.Toxicities of the thrombopoietic growth factors Effect of hepatic or renal impairment on eltrombopag pharmacokinetics.Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura.Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents.Durability and factors associated with long term response after splenectomy for primary immune thrombocytopenia (ITP) and outcome of relapsed or refractory patients.Long-term management of chronic immune thrombocytopenic purpura in adults.Eltrombopag for the treatment of idiopathic thrombocytopenic purpura.Current status of thrombopoietic agents.Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosing.Current treatment options for primary immune thrombocytopenia.Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia.

P2860

Q24235481-8B91C239-0DFC-48FC-84C6-13BBFBB3A09B Q24240685-D4F8B60D-8679-4D7B-A33B-F05309B421CE Q24601161-05D34129-A93C-46D5-9D33-3FDE6EAAA7CE Q26738630-26F6B822-8A43-400A-9A0B-78CBBF977320 Q26779408-972A8F17-8A63-486F-BBC7-4FD03B2A3D34 Q26830732-AFFDE13D-2D60-48C5-B5C2-1E292065E0F6 Q27023294-F8888013-3F1D-4AE0-A984-C700E5A85800 Q27694559-0CECB16A-6347-4E93-B80C-F66CC94F72BC Q28071710-54FB06D4-A409-45A7-A17F-D47E8AC92ED0 Q28074484-FD63A983-A365-45C8-AA7A-32316EF8C0FD Q28085299-A969FF30-9070-4325-B448-51CD926959CA Q28546734-3DB3C68C-85C5-49D1-8356-E2CEEE89388C Q30399669-0FC34666-B0C0-49FA-9455-8E29A7A64C55 Q31089024-E9C5C58D-0A4B-4086-BB31-E29E9B46F250 Q33379632-683B9377-5445-45BE-A7EA-973408DFF7F4 Q33382190-3C569AF9-2B58-4CDF-B3C3-61AF66B2C729 Q33382856-6699008C-39A3-4AD2-B212-16970ACD14E9 Q33384996-9678F52E-3CF9-4463-9539-F9AED69422DE Q33385976-AA26E9F4-C1AF-4621-93EC-0086CC3C3DBC Q33385999-A205531B-2D5B-48F2-8A35-FECBAAFA3CE8 Q33386303-3FA07BA6-8064-4CDB-B1D6-8A03BF3F6076 Q33387153-156A6B76-E7B3-4C30-A768-FA9508AAA139 Q33387735-34773236-37B7-42F4-B88D-84E5CF8D874C Q33387808-2FC960AD-DC71-4F09-B00B-B04CF8ABD25E Q33389236-C04CAE00-706E-4681-A7F3-EBA0A3533EE7 Q33389284-8C982D7E-B1E8-4593-B041-3F6D44E610C4 Q33390001-42C366D8-D57F-412D-990A-F2A11FEE65EA Q33390380-BF54A0A2-6B2C-4CBD-864A-F8075205BC25 Q33390645-91534D22-91B5-4E24-9458-F82475B8D33A Q33391009-029DDB77-1DBA-4510-AADE-3AA00AB316EF Q33391013-B3D4EDE8-F24E-4B2F-BD2A-DE7AAFA2D635 Q33391221-63842B35-C308-4D44-B22F-62963C4B962D Q33392406-50FA180C-CF64-4F86-85C0-0C90F207D176 Q33392610-B441CBE9-DAC6-4970-94A8-A9BBB7C452B0 Q33392852-230C82EB-C12B-4D92-9089-3A38F1FF17DF Q33392858-ECDA167A-9F1E-40E7-B099-3CF3A82FE50D Q33393231-B18F903C-5D22-44AF-8D5C-594A0BB65DF8 Q33394149-5355120C-37D0-4614-9AF2-1A0EE8B240E2 Q33394296-710BC6D5-9F4D-4725-B914-A6BAED662336 Q33394438-E0055D3C-E96C-4BE1-966E-4DEDA778DFEE

P2860

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

http://www.wikidata.org/entity/Q33377602

description

2007 nî lūn-bûn

@nan

2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

@ast

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

@en

type

label

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

@ast

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

@en

prefLabel

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

@ast

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

@en

P1433

Q33377602-FB21D372-11A8-49D7-BE3D-ED72C32C321C

P1476

Q33377602-A755FD37-00FD-4122-BC79-7606FB467670

P2093

Q33377602-353A6AF6-DBCF-40FB-84C4-FDD5962DA357

Q33377602-3A1DA808-9D48-49D2-A7C8-5CCC598FAEA3

Q33377602-3C28298C-917B-4082-9854-EA90F8F0533C

Q33377602-4471C659-3A47-478B-B92A-8C9A9ADBA191

Q33377602-71F15320-228F-4583-A842-0C9EE45970D9

Q33377602-7E471F36-2B58-4589-9584-1EBCD5AA4553

Q33377602-9275213F-6CFB-435A-88AE-52B3348E39F8

Q33377602-95799EAE-630F-4C59-9998-1BD5202C84F2

Q33377602-A1559505-790A-4B39-8E49-2845197E531C

Q33377602-A6BCA00A-5587-4EA6-89C9-E07FD933D479

P304

Q33377602-2522EF39-0846-4495-A0C0-0320A83D8FBA

P31

Q33377602-D79E96E9-5B75-4CD6-9F77-9F987BAB78AF

P356

Q33377602-645DA464-D1E7-4143-9E9A-7638E0F61CB4

P407

Q33377602-52045F3C-5CB7-431A-A190-6DCF12A65E4D

P433

Q33377602-8F4DEC94-0E95-47FF-A371-2634073FEE10

P478

Q33377602-6B7A6A59-7CDA-4C60-8345-CAE590D5003A

P50

Q33377602-31C99352-44BF-45B3-9A6B-B5BAC507A0E0

Q33377602-6E01EC0F-6F42-4BE2-BEEE-B777204F5F1A

P577

Q33377602-11A91779-DCB1-4F46-83E9-C086738E0CBF

P5875

Q33377602-29031745-D6D4-4670-8F05-3C1E73336ED9

P698

Q33377602-43F57E91-B26B-4C15-B1C3-FD52DB083DCF

P921

Q33377602-D187DD24-62FF-4313-B0C8-F9DC57111C61

P356

P1433

The New England Journal of Medicine

P1476

Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

@en

P2093

Balkis Meddeb

http://www.w3.org/2001/XMLSchema#string

Bhabita Mayer

http://www.w3.org/2001/XMLSchema#string

Drew Provan

http://www.w3.org/2001/XMLSchema#string

Gregory Cheng

http://www.w3.org/2001/XMLSchema#string

Habib Hassani

http://www.w3.org/2001/XMLSchema#string

Janusz Kloczko

http://www.w3.org/2001/XMLSchema#string

Julian M Jenkins

http://www.w3.org/2001/XMLSchema#string

Lidia Kovaleva

http://www.w3.org/2001/XMLSchema#string

Mansoor N Saleh

http://www.w3.org/2001/XMLSchema#string

Michael Arning

http://www.w3.org/2001/XMLSchema#string

P304

2237-2247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA073275

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

357

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5801954

http://www.w3.org/2001/XMLSchema#string

P698

18046028

http://www.w3.org/2001/XMLSchema#string

P921

thrombocytopenia